American Shared Hospital Services Dossier - Source-backed chat

American Shared Hospital Services

AMSNYSE

SectorHealth Care

IndustryHealth Care Services

Beta (adjusted)0.54

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.42Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $9.4M

Enterprise Value $19.1M

Shares Outstanding 6.8M diluted

Moat Rating None

Next Earnings Date12 Nov 2026

Last ex-dividend28 Jun 2007

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

American Shared Hospital Services (AMS) is undergoing a significant strategic transition from its traditional, high-margin medical equipment leasing model to a direct patient care services model. While this shift has successfully driven top-line growth—with Q1 2026 revenue rising 15.9% year-over-year to $7.1 million—it has introduced substantial near-term margin compression and operational complexity. Furthermore, the company faces critical balance sheet pressures, including reported covenant defaults and a matured credit facility. Until these capital structure risks are resolved and the direct patient care segment demonstrates a clear path to bottom-line profitability, a cautious Hold stance is warranted.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$4.00

High · most bullish analyst$4.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company is unable to resolve its credit facility defaults or refinance its debt on acceptable terms, leading to liquidity constraints or dilutive capital raises. Operational costs in the direct patient care segment continue to escalate, and further Gamma Knife contract expirations exacerbate revenue declines in the leasing segment, causing wider net losses.

Base CaseCentral scenario

The company successfully navigates its credit facility defaults and stabilizes its capital structure. Direct patient care services continue to expand, offsetting the decline in the leasing segment. Margins gradually recover as newly upgraded Gamma Knife systems and radiation therapy centers ramp up utilization, leading to narrowed net losses by late 2026.

Bull CaseUpside scenario

American Shared Hospital Services (AMS) is successfully transitioning from a traditional medical equipment leasing model to a higher-margin 'Own and Operate' (O&O) direct patient services model. This strategic shift is driving strong top-line momentum, highlighted by a 30.2% year-over-year increase in Direct Patient Care Services revenue in Q1 2026, fueled by expanding patient volumes at its Puebla, Mexico and Rhode Island cancer centers. Furthermore, the company is expanding its footprint with key long-term growth drivers, including the planned construction of a new proton beam radiation treatment (PBRT) center in Johnston, Rhode Island, and a new Gamma Knife facility in Guadalajara, Mexico, allowing AMS to capture greater procedure-level profits and address underserved oncology markets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong top-line momentum in the Direct Patient Care Services segment, which grew 30.2% year-over-year to $4.1 million in Q1 2026.
Long-term revenue visibility secured by the seven-year PBRT lease extension with Orlando Health through 2033.
Active technology upgrades, such as the Gamma Knife Esprit platform installation in Lima, Peru, positioning the company for future volume growth.

Key Investment Risks

Balance sheet and liquidity risks associated with reported credit facility covenant defaults and debt maturity.
Margin compression resulting from the strategic shift toward the lower-margin direct patient care segment and rising operational costs.
Concentration risk and vulnerability to contract expirations, as evidenced by the expiration of three Gamma Knife agreements in late 2025.

Thesis Invalidation Triggers

Failure to resolve credit facility defaults or secure debt refinancing by the end of Q3 2026.
A sequential decline in direct patient care treatment volumes or revenue.
Additional unexpected expirations of major leasing contracts without replacement agreements.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.